louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02414191: Feedback on Perioperative Temperature Management and Patient Outcomes: Three-arm Trial to Compare Feedback
Official title: Effect of Audit and Feedback on Physicians' Perioperative Temperature Management and Patient Outcomes: A Three-arm Cluster Randomized Controlled Trial to Compare Benchmarked and Ranked Feedback
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Surgical Site Infections
Hypothermia
Keywords: Feedback
Temperature management
Anesthesia
Lead sponsor: Ottawa Hospital Research Institute
Sponsor class: OTHER
First posted: 2015-04-10
Enrollment: 45
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The investigators aim to assess the impact of benchmarked and ranked feedback on anesthesiologists' perioperative temperature management and subsequent patient outcomes.


Eligibility criteria: Inclusion Criteria:

* Staff Anesthesiologists at The Ottawa Hospital

Exclusion Criteria:

* none

Primary outcomes:
measure: Patient peri-operative temperature
timeFrame: Within the 30 minutes immediately before or the 15 minutes immediately after anesthesia end time.
Secondary outcomes:
measure: Intraoperative warming device usage perioperative
timeFrame: intraoperative
measure: Patient post-operative surgical site infection (SSI) rate
timeFrame: Within 30 days of surgery
Other outcomes:
Locations:
city: Ottawa
country: Canada
facility: The Ottawa Hospital
state: Ontario
Study officials:
affiliation: The Ottawa Hospital
name: Sylvain Boet, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Boet S, Bryson GL, Taljaard M, Pigford AA, McIsaac DI, Brehaut J, Forster A, Mohamed K, Clavel N, Pysyk C, Grimshaw JM; Canadian Perioperative Anesthesia Clinical Trials Group. Effect of audit and feedback on physicians' intraoperative temperature management and patient outcomes: a three-arm cluster randomized-controlled trial comparing benchmarked and ranked feedback. Can J Anaesth. 2018 Nov;65(11):1196-1209. doi: 10.1007/s12630-018-1205-0. Epub 2018 Aug 29.
Clinical trial NCT04351191: PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds
Official title: Use and Dosage of Hydroxychloroquine and Chloroquine to Convert Symptomatic RT-PCR Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Coronavirus Infectious Disease 2019 (COVID-19) Patients to RT- PCR-Negative as a Means to Reduce Hospitalization Rate
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Sars-CoV2
Symptomatic Condition
Covid-19
Lead sponsor: Government of Punjab, Specialized Healthcare and Medical Education Department
Sponsor class: OTHER_GOV
Collaborators: name: Mayo Hospital Lahore
name: Services Hospital, Lahore
name: Pakistan Kidney and Liver Institute
First posted: 2020-04-17
Enrollment: 137
Sex: ALL
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Prospective double blind randomized superiority clinical trial.
Primary purpose: TREATMENT

Brief summary: To treat Pakistani patients with non-life threatening symptomatic SARS-CoV-2 infection with an intent to reduce burden on institutional healthcare services by determining efficacy of different chloroquine and hydroxychloroquine dosing regimens in controlling SARS-CoV-2 infection.


Eligibility criteria: Inclusion Criteria:

1. Symptomatic patients: defined as fever (temperature greater than 100 degree F), cough, or shortness of breath (respiratory rate \>22 per minute).
2. Nasopharyngeal RT-PCR positive SARS-CoV-2
3. Age 20-50 years
4. BMI 18-28 kg/m2
5. Informed consent

Exclusion Criteria:

1. O2 saturation by pulse-oximeter below 93%
2. Co-morbidities: any pre-existing cardiac disease, pulmonary disease, diabetes
3. Arrhythmias and/or history of arrythmia
4. Psoriasis and/or history of psoriasis
5. Neuropathy or myopathy and/or history of these
6. Hypoglycemia and/or history of hypoglycemia
7. Pre-existing hepatic disease
8. Pre-existing renal disease
9. Use of antacids within 1 week
10. Use of antiobiotics within 1 week
11. Pregnancy
12. RT-PCR performed \>7 days prior to enrollment

Primary outcomes:
measure: RT-PCR result
timeFrame: 6th and 7th day
Secondary outcomes:
measure: Progression of symptoms
timeFrame: 7 days
measure: Mortality
timeFrame: 30 days
Other outcomes:
Locations:
city: Lahore
country: Pakistan
facility: Expo Covid Isolation Center / Mayo Hospital Field Hospital
state: Punjab
city: Lahore
country: Pakistan
facility: Mayo Hospital / King Edward Medical University
state: Punjab
city: Lahore
country: Pakistan
facility: Pakistan Kidney and Liver Institute
state: Punjab
city: Lahore
country: Pakistan
facility: Services Hospital
state: Punjab
Study officials:
affiliation: Beth Israel Deaconess Medical Center
name: Ammar Sarwar, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05361291: Evaluation of the Effect of Adding Dexamethasone to 2% Lidocaine
Official title: Comparative Evaluation of Adding Dexamethasone to 2% Lidocaine (With and Without Epinephrine) on the Anesthetic Success Rate of Inferior Alveolar Nerve Block in Patients With Symptomatic Irreversible Pulpitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pulpitis - Irreversible
Lead sponsor: Jamia Millia Islamia
Sponsor class: OTHER
First posted: 2022-05-04
Enrollment: 124
Sex: ALL
Minimum age (years): 18
Maximum age (years): 59
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This randomized, double-blind clinical trial aimed at the evaluation of the effect of adding dexamethasone to 2% lidocaine, given as inferior alveolar nerve block in the endodontic management of symptomatic irreversible pulpitis. One hundred and twenty four patients received one of the three IANB injections before the endodontic treatment: 2% lidocaine with 1:80 000 epinephrine; 2% lidocaine with 1:80 000 epinephrine mixed with 2mg dexamethasone; and plain 2% lidocaine mixed with 2mg dexamethasone. The anesthetia was considered successful if the patients experienced no pain or faint/weak/mild pain during root canal access preparation and instrumentation (HP VAS score \<55 mm). The effect of intraligamentary injections on maximum heart rates was also recorded.


Eligibility criteria: Inclusion Criteria:

* absence of any periapical radiolucency on radiographs, except for a widened periodontal ligament
* active pain in a mandibular molar
* prolonged response to cold testing with an ice stick and an electric pulp tester
* vital coronal pulp on access opening and ability to understand the use of pain scales

Exclusion Criteria:

* a history of known or suspected drug abuse
* history of active peptic ulcer within the preceding 12 months
* history of bleeding problems or anticoagulant use within the last month
* known allergy, sensitivity, or contraindications to any opioid or nonopioid analgesic including aspirin or NSAIDs
* patients who had taken NSAIDs within 12 h before administration of the study drugs
* patients who were pregnant or breast-feeding

Primary outcomes:
measure: Anesthtic success
timeFrame: 15 minutes after the inferior alveolar nerve block
Secondary outcomes:
measure: Heart Rate
timeFrame: After 1 minutes of initial injection
Other outcomes:
Locations:
city: New Delhi
country: India
facility: Faculty of Dentistry, Jamia MIliia Islamia
Study officials:
References:
Clinical trial NCT00364091: Evaluation of Efficacy of Ophthalmic Solution in Seasonal Allergic Conjunctivitis
Official title: A Multi-Center, Randomized, Double-Masked Parallel Group Study Evaluating the Efficacy, Safety, and QOL of R89674 0.25% Ophthalmic Solution Compared to Vehicle or an Active Control in a Modified Model of Environmental Seasonal Allergic Conjunctivitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Allergic Conjunctivitis
Keywords: allergic conjunctivitis, ophthalmology, multicenter, controlled
Lead sponsor: Vistakon Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2006-08-15
Enrollment: 365
Sex: ALL
Minimum age (years): 10
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this summary is to evaluate the efficacy and safety of R89674 0.025% ophthalmic solution compared with placebo or an active control in subjects with seasonal allergic conjunctivitis


Eligibility criteria: Inclusion Criteria:

* history of positive diagnostic test for ragweed within the past 2 years;
* positive bilateral response to ragweed as induced by conjunctival allergen challenge

Exclusion Criteria:

* ocular infection;
* history of retinal detachment, diabetic neuropathy, or any progressive retinal disease;
* moderate to severe asthma;
* dry eye syndrome;
* history of severe, unstable, or uncontrolled cardiovascular, pulmonary, hepatic, renal or autoimmune disease;
* pregnancy or lactation

Primary outcomes:
measure: Ocular itching and redness scores at defined timepoints
Secondary outcomes:
measure: QOL, severity of chemosis & redness, ocular itching and redness scores at defined timepoints
Other outcomes:
Locations:
city: Louisville
country: United States
state: Kentucky
city: North Andover
country: United States
state: Massachusetts
city: Creve Coeur
country: United States
state: Missouri
city: Charlotte
country: United States
state: North Carolina
city: Philadelphia
country: United States
state: Pennsylvania
city: Memphis
country: United States
state: Tennessee
Study officials:
affiliation: Vistakon Pharmaceuticals
name: Reza Haque, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01890291: Long Term Follow-Up Study of Immuncell-LC Group and Non-Treatment Group in Hepatocellular Carcinoma Patients.
Official title: Long Term Study of 'Immuncell-LC Groups' and 'Non-treatment Groups' in Patient Undergo Curative Resection (PEIT, Radiofrequency Ablation [RFA] or Operation) for Hepatocellular Carcinoma in Korea
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hepatocellular Carcinoma
Keywords: Immuncell-LC, Hepatocellular carcinoma
Lead sponsor: GC Cell Corporation
Sponsor class: INDUSTRY
First posted: 2013-07-01
Enrollment: 162
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: This long term follow-UP study is observation about the Immuncell-LC Groups' and 'Non-treatment Groups' in patient undergo curative resection (PEIT, RFA or Operation) for Hepatocelluar Carcinoma in Korea.

Brief summary: To observation that long term follow-up study of 'Immuncell-LC groups' and 'Non-treatment groups' in patient undergo curative resection (PEIT, RFA or Operation) for hepatocellular carcinoma in Korea


Eligibility criteria: Inclusion Criteria:

* Prior to the test, patient is fully explained about the purpose/ contents and characteristics of the testing medication, and the patient him(her)self, the guardian or the legal representative signed on written consent.
* Patients of participated in the(ClinicalTrials.gov Identifier:NCT00699816)clinical trial.

Exclusion Criteria:

* Patient who is incongruent to this clinical trial by sub-investigator's opinion.

Primary outcomes:
measure: To evaluate recurrence-free survival
timeFrame: up to 3 years
Secondary outcomes:
measure: To determine the response rate to evaluate overall survival and cause specific survival and changes of Alpha feto protein (AFP) figures from baseline to the last observation date.
timeFrame: up to 3 years
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National Hospital
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
city: Seoul
country: Korea, Republic of
facility: Korea University Guro Hospital
city: Seoul
country: Korea, Republic of
facility: Korea University Ansan Hospital
Study officials:
affiliation: Seoul National University Hospital
name: Jung Hwan Yoon, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Samsung Medical Center
name: Joon Hyeok Lee, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Asan Medical Center
name: Young-Suk Lim, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Korea University Ansan Hospital
name: Tae Gin Song, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Korea University Guro Hospital
name: Jong Eun Yeon, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03242291: Evaluation of Marginal Integrity of Hydroxyapatite Nano-Fiber Reinforced Flowable Composite Versus Conventional Resin-Based Flowable Composite in Initially Demineralized Pits and Fissure: A One Year, Randomized Clinical Trial
Official title: Evaluation of Marginal Integrity of Hydroxyapatite Nano-Fiber Reinforced Flowable Composite Versus Conventional Resin-Based Flowable Composite in Initially Demineralized Pits and Fissure: A One Year, Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Marginal Integrity of Hydroxyapatite Nanofiber Reinforced Flowable Composite
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2017-08-08
Enrollment: 26
Sex: ALL
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study will be conducted to evaluate the Marginal integrity of Hydroxyapatite Nanofiber reinforced flowable composite compared to a conventional resin-based flowable composite during management of initial carious lesion in adult population over a one year period.

Detailed description: A total of 26 volunteer patients with at least 2 non-cavitated molar teeth will be assigned in this study. Patients will be divided into two groups according to type of flowable composite (R) where groups R1 the pits and fissure will be sealed with Hydroxyapatite Nanofiber reinforced flowable composite while groups R2 the pits and fissure will be sealed with conventional resin-based flowable composite. Each restoration will be assessed after one week, six and twelve months Both materials will be applied according to manufacturer's instructions where teeth should be cleaned to remove surface stains, then select appropriate shade of the flowable composite, A rubber dam is the preferred method of isolation, etch and rinse adhesive system is applied, where acid etching will be applied for 15 seconds then rinse and dry followed by application of adhesive then light cure 10 seconds, then place and cure in 2 mm increments of the flowable composite for 20 s., gently remove oxygen inhibition layer after light cure with slurry of pumice or polishing paste All restorations were reviewed after 1 week, 6, 12 months by two investigators who were blinded to the material used for the restorations. All restorations were be evaluated by calibrated examiners following the FDI criteria

Eligibility criteria: Inclusion Criteria:

* Patients should be over 18 Years old.
* Patient should have good oral hygiene and general health
* With at least 2 non-cavitated initial occlusal carious lesion first and/or Second molar teeth in each quadrant of maxilla or mandible

Exclusion Criteria:

* Known allergy to any of the resins used,
* Clinically detectable caries,
* Previously placed sealants or restorations,
* Bruxism or malocclusion

Primary outcomes:
measure: marginal integrity of both restorations
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02217891: IFACT: Incidental Findings in Advanced Cancer Therapy
Official title: IFACT: Incidental Findings in Advanced Cancer Therapy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Breast Cancer
Colorectal Cancer
Bladder Cancer
Lung Cancer
Lead sponsor: Memorial Sloan Kettering Cancer Center
Sponsor class: OTHER
First posted: 2014-08-15
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CROSSOVER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: IFACT study participants will be recruited from existing MSK protocol #12-245.

Brief summary: The proposed study, IFACT - Incidental Findings in Advanced Cancer Therapy, will address this research gap by examining MSK patients' attitudes, preferences, and information needs regarding incidental findings arising from tumor genomic profiling.

Detailed description: Part 1, the investigators will recruit 40 participants from those already enrolled in existing MSK IRB protocol #12-245 (PI: David Hyman, MD) including male and female patients who have been diagnosed with late-stage breast, colorectal, bladder, and lung cancer (some of the most common cancers in this study population).

Part 2, the investigators will recruit 20 participants from those who have actually received incidental germline findings from MSK IRB protocol #12-245 Consent Part C in order to cognitively test novel survey items about their knowledge and perceived utility of their incidental findings (note that the content of these items will be derived from the data collected in Part 1)

Eligibility criteria: Inclusion Criteria:

Part 1:

* Patient enrolled on MSK protocol #12-245
* Living patient age 18 or older
* Patient diagnosed with breast cancer, colorectal cancer, bladder cancer, or lung cancer
* Patient residing in New York metro-area

Part 2:

* Living patient age 18 or older
* Consented to Part C of IRB#12-245 and has received results regardless if thereir was a pathogenic variant
* Patient diagnosed with cancer type approved for IRB#12-245 Part C (which are currently breast cancer, gynecological cancer, prostate cancer, and GU non-prostate cancer)breast cancer, colorectal cancer, bladder cancer, or lung cancer
* Patient residing in New York metro-area

Exclusion Criteria for Part 1 and 2:

* Non-English speakers because we do not have the resources to conduct and translate the interviews into other languages.
* Patient unwilling or unable to provide informed consent.

Primary outcomes:
measure: qualitive data
timeFrame: one time
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: Jada Hamilton, PhD, MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05939791: Physical Exercise and Dairy Probiotics in Childhood Cancer Survivors
Official title: The Effect of Physical Exercise and Dairy Probiotics (Lactobacillus Casei) on Gut Microbiome in Childhood Cancer Survivors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Acute Lymphoblastic Leukemia, Pediatric
Keywords: Physical Exercise, Gut Microbiome, Exercise Training, Veillonella
Lead sponsor: Comenius University
Sponsor class: OTHER
First posted: 2023-07-11
Enrollment: 29
Sex: ALL
Minimum age (years): 6
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The goal of this clinical trial is to to compare the structure of the intestinal microbiome between children shortly after treatment for acute lymphoblastic leukemia (1-3 years after cancer treatment) and healthy controls. And then to provoke a positive shift of bacterial diversity by physical activity and probiotics in cured pediatric oncology patients with persistent gut microbiome disruptions.

The main question\[s\] it aims to answer are:

* Are differences in bacterial richness between healthy controls and pediatric oncology patients ≥12 months after cancer treatment apparent?
* Has the combination of physical exercise and probiotics had a positive influence on the structure of the gut microbiome in childhood cancer survivors in remission? Two times per week of physical activity and daily dairy consumption with probiotics will be required of participants for eight weeks.


Eligibility criteria: Inclusion Criteria:

- children previously diagnosed and treated for acute lymphoblastic leukemia in remission between 1 and 3 years

Exclusion Criteria:

* acute respiratory infection during intervention
* more than 20% skipped exercise training sessions

Primary outcomes:
measure: The shift of gut microbiome by physical exercise and consumption of dairy probiotics.
timeFrame: 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Bratislava
country: Slovakia
facility: Department of Pediatric Hematology National Institute of Children's Diseases Bratislava
Study officials:
References:
Clinical trial NCT02680691: Robot Assisted Gait Training in Patients With Infratentorial Stroke
Official title: The Effect of Robot Assisted Gait Training in Patients With Infratentorial Stroke
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Stroke
Keywords: infratentorial stroke
robot
postural balance
Rehabilitation
Lead sponsor: National Rehabilitation Center, Seoul, Korea
Sponsor class: OTHER_GOV
First posted: 2016-02-11
Enrollment: 19
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The Effect of Robot Assisted Gait Training in Patients With Infratentorial Stroke

Detailed description: The hypothesis is to determine the robotic gait training would be better than conventional therapy regarding the postural balance.

Eligibility criteria: Inclusion Criteria:

* Patients with infratentorial stroke
* Cognitively intact enough to understand and follow the instructions from the investigator

Exclusion Criteria:

* chronic neurological pathology
* orthopedic injuries
* femur lengths of less than 34cm
* severely limited range of lower extremity joint motion
* medical instability

Primary outcomes:
measure: Change From Baseline in Berg Balance Scale at 4 Weeks
timeFrame: Baseline and 4 weeks from baseline
Secondary outcomes:
measure: Berg Balance Scale
timeFrame: Baseline, 4 weeks from baseline, 8 weeks from baseline, 12 weeks from baseline
measure: Trunk impairment scale
timeFrame: Baseline, 4 weeks from baseline, 8 weeks from baseline, 12 weeks from baseline
measure: Functional Ambulation Category
timeFrame: Baseline, 4 weeks from baseline, 8 weeks from baseline, 12 weeks from baseline
measure: 10m walk test
timeFrame: Baseline, 4 weeks from baseline, 8 weeks from baseline, 12 weeks from baseline
measure: Fugl-Meyer Assessment
timeFrame: Baseline, 4 weeks from baseline, 8 weeks from baseline, 12 weeks from baseline
measure: Korean version of Falls efficacy scale
timeFrame: Baseline, 4 weeks from baseline, 8 weeks from baseline, 12 weeks from baseline
measure: Scale for the assessment and rating of ataxia
timeFrame: Baseline, 4 weeks from baseline, 8 weeks from baseline, 12 weeks from baseline
measure: Balance test using force plate
timeFrame: Baseline, 4 weeks from baseline, 8 weeks from baseline, 12 weeks from baseline
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: National Rehabilitation Center
Study officials:
affiliation: National Rehabilitation Center
name: Joon-Ho Shin, MS
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kim HY, Shin JH, Yang SP, Shin MA, Lee SH. Robot-assisted gait training for balance and lower extremity function in patients with infratentorial stroke: a single-blinded randomized controlled trial. J Neuroeng Rehabil. 2019 Jul 29;16(1):99. doi: 10.1186/s12984-019-0553-5.